axiom insights is offering advanced X-ray Fluorescence Imaging as a breakthrough in-vivo tracking method: new data for new insights

axiom insights provides advanced X-ray Fluorescence Imaging (XFI) as an individual & customer-oriented specific on-demand service to pharma & cosmetic industries, biotech companies and scientific research teams to secure clinical pathways by providing new data for new insights:

  • in-vivo tracking for cell and gene therapy
  • in-vivo tracking of labeled immune cells (e.g. for immune-mediated inflammatory diseases, like autoimmune hepatites, nephritis, multiple-sklerosis, and inflammatory bowel disease)
  • in-vivo tracking of nanomedicine carriers (e.g. functionalized nanoparticles): drug delivery and drug release, toxicology
  • in-vivo tracking of antibodies and/or medical drugs (via functionalized nanoparticles) for pharmacokinetic and pharmacodynamic studies


  • precise localization & quantification for assessment of in-vivo biodistribution
  • in-vivo tracking in real-time and over arbitrary long time-windows
  • in-vitro assay for new ligands and/or cell uptake 

Our new data can help getting new insights for a deeper understanding and direct in-vivo access for innovative drug development and therapy approaches, hence reducing significant R&D investment and cost of pre-clinical trial by increasing in-market time and higher ROI. 

Our office is based in Hamburg at DESY’s Innovation Village in direct vicinity to one of the worlds most brilliant synchrotron X-ray source (PETRA III) - a perfect environment to offer high quality science-based services.

Our Vision is to provide new insights by new data.

Biomedical Imaging

axiom insights’s solutions are based on X-ray Fluorescence Imaging (XFI). In contrast to optical fluorescence, XFI uses nanoparticles that emit X-ray fluorescence signals whenever hit by a scanning X-ray beam. Medical drugs and/or antibodies can be bound to the surface of nanoparticles, or cells can be loaded with them. In any case, XFI allows the quantitative in-vivo localization of the nanoparticle-coupled molecules and/or labeled cells. This opens new paths to support customers with data that are as of yet not accessible. Our various methods are all IP-protected.